| Bioactivity | Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC50 of 2.99 nM against human recombinant DPP IV. Garvagliptin (ZYDPLA1) exhibits antihyperglycemic effect[1]. |
| In Vivo | Garvagliptin (ZYDPLA1, 30 mg/kg, orally) 在小鼠和大鼠体内提高了循环中的 GLP-1 和胰岛素水平，并表现出剂量依赖性的抗高血糖作用。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| CAS | 1601479-87-1 |
| Formula | C18H23F2N3O3S |
| Molar Mass | 399.46 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Poonam Giri,Sensitive and specific LC-ESI-MS/MS method for determination of ZYDPLA1, a novel long-acting dipeptidyl peptidase 4 inhibitor in rat plasma: An application for toxicokinetic study in rats. Biomed Chromatogr. 2017 Nov;31(11). [2]. Mason, V.L., et al. 16th International Congress of Endocrinology/96th Annual Meeting and Exposition of the Endocrine Society (ICE/ENDO), Chicago, Illinois, USA-June 21-24, 2014. Drugs of the Future v. 39, n. 9 (2014) : 0661. |
Garvagliptin
CAS: 1601479-87-1 F: C18H23F2N3O3S W: 399.46
Garvagliptin (ZYDPLA1) is an orally active, competitive and long acting DPP4 Inhibitor, with an IC50 of 2.99 nM against
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.